You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: January 30, 2026

Details for New Drug Application (NDA): 009434

✉ Email this page to a colleague

« Back to Dashboard

NDA 009434 describes SERPASIL, which is a drug marketed by Novartis and is included in four NDAs. Additional details are available on the SERPASIL profile page.

The generic ingredient in SERPASIL is hydrochlorothiazide; reserpine. There are thirty-two drug master file entries for this compound. Additional details are available on the hydrochlorothiazide; reserpine profile page.

Summary for 009434

Tradename:	SERPASIL
Applicant:	Novartis
Ingredient:	reserpine
Patents:	0

Medical Subject Heading (MeSH) Categories for 009434

Adrenergic Uptake Inhibitors
Antihypertensive Agents
Antipsychotic Agents

Profile for product number 002

Active Rx/OTC/Discontinued:	DISCN	Dosage:	INJECTABLE;INJECTION			Strength	2.5MG/ML
Approval Date:	Approved Prior to Jan 1, 1982	TE:		RLD:	No

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.